Company
Every investor coverage indicates participated in a round Illumina raised.
Companies Illumina acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Illumina. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian genomics spin-out Longas has come out of stealth with technology that extends DNA sequencing read length, backed by the MRCF and its founders, and appoints Solexa's founding chief executive Nick McCooke as CEO.
A university spin-out launches with venture and founder backing, introducing a technology that extends DNA sequencing read lengths, and appointing a new chief executive to commercialise it.